Call Us: 1.800.873.5297


Doctors Criticize Low Testosterone Drug Manufacturers’ Marketing Ploy During Men’s Health Week

Two Dartmouth doctors are criticizing low testosterone therapy manufacturers for their marketing tactics of the Low-T therapy during Men’s Health Week. The event is sponsored by AbbVie and Pfizer, two key manufacturers of testosterone replacement products. While Men’s Health Week is a campaign designed to “heighten the awareness of preventable health problems” among men and boys, […]


Testosterone Drugs Cause Heart Attacks, Strokes, and Blood Clots, New Lawsuits Claim

According to five lawsuits recently filed in the United States District Court for the Northern District of Illinois, the Testosterone replacement drug, AndroGel, is allegedly linked to causing serious medical problems, including life threatening heart attacks, strokes, and blood clots. The cases are Aurecchia v. AbbVie, Case No. 14-cv-00772; Benn v. AbbVie, Case No. 14-cv-00774; […]


Recent Study Concludes that Users of Testosterone Supplements at Increased Risk of Heart Attack or Stroke

ABC News reported on a study published by the Journal of the American Medical Association (JAMA), which followed more than 8,000 male veterans with low testosterone. After comparing cardiovascular events in males taking a testosterone supplement with those who were not taking such supplements, the study concluded that men who used a supplement were 29% […]


New Research: Testosterone Drugs Linked to Increased Risk of Blood Clots, Heart Attack and Stroke

The FDA recently announced the launch of an investigation of the cardiovascular risks associated with testosterone therapy. The medical safety alert is to warn men of potential risks and/or side effects associated with testosterone therapy. Studies have shown that, as early as one month and up to the first 90 days after starting testosterone therapy, dangerous […]


New Research Suggests that Testosterone Drugs Linked to Increased Risk of Heart Attacks, Strokes

Testosterone is used in men and boys to treat conditions caused by a lack of this hormone. Use of testosterone drugs has increased over the past decade, particularly in the United States, with dramatic shifts from injections to gels. Sales of testosterone gels and creams have dramatically increased despite the fact that long-term effects associated […]


FDA Issues Warning for Serious Effects From Children in Contact with Users of Testosterone Gel

Young children are reportedly developing premature or inappropriate sexual organs from their contact with adult users of testosterone gel. Specifically, young girls developed male sex characteristics, and boys prematurely developed male sex characteristics. The FDA is now requiring two testosterone gel products to have a boxed label warning of these serious side effects. The gels […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.